ADORA2A and neoplasm: With increased tumor PD-L1, the expression of inhibitory checkpoint molecules (ICMs), including ADORA2A, BTLA, CD160, and PDCD1, was downregulated while the expression of IDO1 was upregulated (Figure 5A).